# Safety and Efficacy Study of LUM001 in the Treatment of Cholestatic Liver Disease in Patients With Alagille Syndrome

> **NCT01903460** · PHASE2 · COMPLETED · sponsor: **Mirum Pharmaceuticals, Inc.** · enrollment: 20 (actual)

## Conditions studied

- Alagille Syndrome

## Interventions

- **DRUG:** LUM001
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01903460
- **Lead sponsor:** Mirum Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-08
- **Primary completion:** 2015-02
- **Final completion:** 2015-03
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2019-03-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01903460

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01903460, "Safety and Efficacy Study of LUM001 in the Treatment of Cholestatic Liver Disease in Patients With Alagille Syndrome". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01903460. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*